Regulation of resistance to tyrosine kinase inhibitors for patients with chronic myeloid leukemia

Abstract

The application of tyrosine kinase inhibitors (TKI) has revolutionized the treatment of chronic myeloid leukemia (CML), but with its widespread use in clinical applications, drug resistance has become a huge challenge in clinical treatment. The development of the second and third generation of TKI, and some new drugs brought new treatment options and hopes for imatinib of the first generation of TKI resistant patients. The continuous improvement of the therapeutic effect monitoring system and the application of ABL kinase domain mutation detection provide an objective and sensitive index for the selection of TKI. Therefore, only the combination of therapeutic drugs and the corresponding monitoring system can make the patients get more reasonable and standardized treatment. In this paper, research progress of selection of treatment regimen and monitoring system of effect for CML patients who were resistance to TKI are reviewed. Key words: Leukemia, myelogenous, chronic, BCR-ABL positive; Protein-tyrosine kinases; Proteinkinase inhibitors; Molecular monitoring